Successful treatment of severe refractory post-cesarean pyoderma gangrenosum with intravenous immunoglobulin

Simple item page
dc.contributor.authorGündüz K.
dc.contributor.authorGülbaşaran F.
dc.contributor.authorHasdemir P.S.
dc.contributor.authorTemiz P.
dc.contributor.authorInanır I.
dc.date.accessioned2024-07-22T08:07:03Z
dc.date.available2024-07-22T08:07:03Z
dc.date.issued2020
dc.description.abstractPyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by rapidly progressing necrolytic ulceration of the skin. Proper treatment is crucial since it can result in devastating consequences. First-line treatments include systemic corticosteroids or cyclosporine. However, no standardized treatment regimens for refractory cases exist and treatment outcomes are affected by underlying conditions. PG after cesarean section, which is believed to occur in association with underlying pregnancy- and parturition-related immune changes, is extremely rare, and all reported cases in the literature have been successfully treated with systemic or topical corticosteroids. We report a case of a 32-year-old patient with severe PG occurring on her cesarean scar 3 days after the cesarean delivery. Treatment with systemic corticosteroids and first-line immunomodulatory agents resulted in insufficient response and serious complications. Intravenous immunoglobulin (IVIG) was then initiated, and a rapid clinical response was seen. Corticosteroid dose was gradually decreased and ceased. IVIG infusion was continued for 3 months until complete recovery. Reactivation was not observed in a 1-year follow-up period. Due to its cost, IVIG infusion is less suitable as a first-line agent. However, IVIG may be an important therapeutic option in resistant postpartum PG, in which first-line agents have failed or led to complications. © 2020 Wiley Periodicals LLC.
dc.identifier.DOI-ID10.1111/dth.14121
dc.identifier.issn13960296
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13804
dc.language.isoEnglish
dc.publisherBlackwell Publishing Inc.
dc.rightsAll Open Access; Gold Open Access
dc.subjectAdrenal Cortex Hormones
dc.subjectAdult
dc.subjectCesarean Section
dc.subjectCyclosporine
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunoglobulins, Intravenous
dc.subjectPregnancy
dc.subjectPyoderma Gangrenosum
dc.subjectalprazolam
dc.subjectantibiotic agent
dc.subjectanticoagulant agent
dc.subjectantiinfective agent
dc.subjectcalcium
dc.subjectcorticosteroid
dc.subjectcyclosporine
dc.subjectenoxaparin
dc.subjectimmunoglobulin
dc.subjectimmunomodulating agent
dc.subjectisoniazid
dc.subjectmethylprednisolone
dc.subjectnonsteroid antiinflammatory agent
dc.subjectsalazosulfapyridine
dc.subjecttumor necrosis factor inhibitor
dc.subjectvitamin D
dc.subjectwarfarin
dc.subjectcorticosteroid
dc.subjectcyclosporine
dc.subjectimmunoglobulin
dc.subjectadjuvant therapy
dc.subjectadult
dc.subjectArticle
dc.subjectatrophic scar
dc.subjectcase report
dc.subjectcesarean section
dc.subjectchildbirth
dc.subjectclinical article
dc.subjectcorticosteroid therapy
dc.subjectCushingoid syndrome
dc.subjectdeep vein thrombosis
dc.subjectdisease severity
dc.subjectdrug cost
dc.subjectdrug dose reduction
dc.subjectdrug substitution
dc.subjectdrug withdrawal
dc.subjectfemale
dc.subjectfollow up
dc.subjectgranulation tissue
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjecthypertransaminasemia
dc.subjecthypertrichosis
dc.subjectmaculopapular rash
dc.subjectmuscle weakness
dc.subjectnecrotizing fasciitis
dc.subjectneutrophilia
dc.subjectpregnancy
dc.subjectpuerperium
dc.subjectpyoderma gangrenosum
dc.subjectremission
dc.subjectrisk reduction
dc.subjectskin necrosis
dc.subjectskin ulcer
dc.subjectstria
dc.subjectsurgical debridement
dc.subjectsystemic therapy
dc.subjecttachycardia
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjectulcer healing
dc.subjectwound dehiscence
dc.subjectadverse event
dc.subjectcesarean section
dc.subjectpyoderma gangrenosum
dc.titleSuccessful treatment of severe refractory post-cesarean pyoderma gangrenosum with intravenous immunoglobulin
dc.typeArticle

Files

Collections

Scopus Koleksiyonu